Benzinga | Sep 14, 2021 10:02AM EDT

Maxim Group Initiates Coverage On Dermata Therapeutics with Buy Rating, Announces Price Target of $9

Maxim Group analyst Anthony Vendetti initiates coverage on Dermata Therapeutics (NASDAQ:DRMA) with a Buy rating and announces Price Target of $9.